Down Syndrome - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：52頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Down Syndrome - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Down Syndrome - Pipeline Review, H1 2014’, provides an overview of the Down Syndrome’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Down Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Down Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Down Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Down Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Down Syndrome - Pipeline Review, H1 2014’, provides an overview of the Down Syndrome’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Down Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Down Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Down Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Down Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Down Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Down Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Down Syndrome - Overview 7
Pipeline Products for Down Syndrome - Comparative Analysis 8
Down Syndrome - Therapeutics under Development by Companies 9
Down Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Down Syndrome - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Down Syndrome - Products under Development by Companies 14
Down Syndrome - Products under Investigation by Universities/Institutes 15
Down Syndrome - Companies Involved in Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Exonhit S.A. 17
Eisai Co., Ltd. 18
Elan Corporation, plc 19
AC Immune SA 20
NeuroNascent, Inc. 21
Selvita S.A 22
Balance Therapeutics, Inc. 23
Down Syndrome - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
ELND-005 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
donepezil hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RG-1662 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BTD-001 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rivastigmine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ACI-24 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NNI-351 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SEL-141 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase Inhibitors Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Down Syndrome - Recent Pipeline Updates 45
Down Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 49
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 49
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 49
Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52
List of Tables
Number of Products under Development for Down Syndrome, H1 2014 7
Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 16
Down Syndrome - Pipeline by Exonhit S.A., H1 2014 17
Down Syndrome - Pipeline by Eisai Co., Ltd., H1 2014 18
Down Syndrome - Pipeline by Elan Corporation, plc, H1 2014 19
Down Syndrome - Pipeline by AC Immune SA, H1 2014 20
Down Syndrome - Pipeline by NeuroNascent, Inc., H1 2014 21
Down Syndrome - Pipeline by Selvita S.A, H1 2014 22
Down Syndrome - Pipeline by Balance Therapeutics, Inc., H1 2014 23
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Down Syndrome Therapeutics - Recent Pipeline Updates, H1 2014 45
List of Figures
Number of Products under Development for Down Syndrome, H1 2014 7
Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Down Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Down Syndrome - Overview 7
Pipeline Products for Down Syndrome - Comparative Analysis 8
Down Syndrome - Therapeutics under Development by Companies 9
Down Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Down Syndrome - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Down Syndrome - Products under Development by Companies 14
Down Syndrome - Products under Investigation by Universities/Institutes 15
Down Syndrome - Companies Involved in Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Exonhit S.A. 17
Eisai Co., Ltd. 18
Elan Corporation, plc 19
AC Immune SA 20
NeuroNascent, Inc. 21
Selvita S.A 22
Balance Therapeutics, Inc. 23
Down Syndrome - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
ELND-005 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
donepezil hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RG-1662 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BTD-001 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rivastigmine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ACI-24 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NNI-351 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SEL-141 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase Inhibitors Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Down Syndrome - Recent Pipeline Updates 45
Down Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 49
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 49
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 49
Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52
List of Tables
Number of Products under Development for Down Syndrome, H1 2014 7
Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 16
Down Syndrome - Pipeline by Exonhit S.A., H1 2014 17
Down Syndrome - Pipeline by Eisai Co., Ltd., H1 2014 18
Down Syndrome - Pipeline by Elan Corporation, plc, H1 2014 19
Down Syndrome - Pipeline by AC Immune SA, H1 2014 20
Down Syndrome - Pipeline by NeuroNascent, Inc., H1 2014 21
Down Syndrome - Pipeline by Selvita S.A, H1 2014 22
Down Syndrome - Pipeline by Balance Therapeutics, Inc., H1 2014 23
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Down Syndrome Therapeutics - Recent Pipeline Updates, H1 2014 45
List of Figures
Number of Products under Development for Down Syndrome, H1 2014 7
Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33
